Therefore, celastrol is effective for inhibiting FASN-mediated liver steatosis in AKT/c-Met HCC mice, which is beneficial for preventing HCC, and so it might be considered as a therapeutic agent for metabolic diseases. This evidence concerns the gene MET and Other metabolic disease.